Oncological outcomes of tumor ablation compared to surgical resection in early-stage hepatocellular carcinomas: a systematic review with meta-analysis
HPB · 2024
DOI: 10.1016/j.hpb.2024.08.008 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HPB, 2024. Verfasst von Janyssa Charbonneau und 6 weiteren Autor:innen. Beteiligte Einrichtung: Université Laval, 1050 Avenue de la Médecine, G1V 0A6, Québec, QC, Canada. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy, Neoplasm Staging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The optimal choice of treatment for early-stage hepatocellular carcinomas (HCC) remains controversial, with recent conflicted guidelines. This systematic review evaluated whether ablation is oncologically non-inferior to surgical resection. METHODS: We performed a systematic search of the EMBASE, MEDLINE, CENTRAL and Web of Science databases to identify randomized controlled trials comparing tumor ablation and surgical resection for early-stage HCCs. A non-inferiority margin of 5% (RR 0.93) for overall survival (OS) was considered, following a consensus of clinical experts. RESULTS: We identified 5829 citations from which 11 trials (n = 1736) were included. The non-inferiority of tumor ablation was not observed for OS (RR 0.92; 95%CI 0.85-1.00,I2 = 33%). Recurrence-free survival was reduced with ablation (RR 0.80; 95%CI 0.69-0.93,I2 = 49%). There was no difference in terms of extra-hepatic recurrence and minor complications. Tumor ablation was associated with decreased overall morbidity (RR 0.43; 95%CI 0.30-0.62,I2 = 31%) and major complications (RR 0.22; 95%CI 0.07-0.71,I2 = 66%). Intra-hepatic recurrence was higher with ablation (RR 1.28; 95%CI 1.10-1.48,I2 = 12%). Certainty of evidence was low to moderate. CONCLUSION: We did not observe the oncological non-inferiority of tumor ablation when compared to surgical resection. Nevertheless, most analyses were of low quality of evidence, including the overall survival. We cannot exclude that the true effect of tumor ablation is different than the currently observed one.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Université Laval, 1050 Avenue de la Médecine, G1V 0A6, Québec, QC, Canada.
- Université Laval, 1050 Avenue de la Médecine, G1V 0A6, Québec, QC, Canada; Centre Hospitalier Universitaire de Québec-Université Laval, 11 Côte du Palais, G1R 2J6, Québec, QC, Canada.
- Université Laval, 1050 Avenue de la Médecine, G1V 0A6, Québec, QC, Canada; Centre Hospitalier Universitaire de Québec-Université Laval, 11 Côte du Palais, G1R 2J6, Québec, QC, Canada. Electronic address: alexandre.brind…
Zitieren
APA
Charbonneau, J., Couture, T., Turgeon, A., O'Connor, S., Ouellet, J. F., Ouellet, J. B., & Brind'Amour, A. (2024). Oncological outcomes of tumor ablation compared to surgical resection in early-stage hepatocellular carcinomas: a systematic review with meta-analysis. HPB. https://doi.org/10.1016/j.hpb.2024.08.008
Vancouver
Charbonneau J, Couture T, Turgeon A, O'Connor S, Ouellet JF, Ouellet JB, et al. Oncological outcomes of tumor ablation compared to surgical resection in early-stage hepatocellular carcinomas: a systematic review with meta-analysis. HPB. 2024. doi:10.1016/j.hpb.2024.08.008
BibTeX
@article{Charbonneau2024,
author = {Charbonneau, Janyssa and Couture, Thomas and Turgeon, Alexis and O'Connor, Sarah and Ouellet, Jean-François and Ouellet, Jean-François Berthin and Brind'Amour, Alexandre},
title = {Oncological outcomes of tumor ablation compared to surgical resection in early-stage hepatocellular carcinomas: a systematic review with meta-analysis},
journal = {HPB},
year = {2024},
doi = {10.1016/j.hpb.2024.08.008}
}
EUVIMED